Luxfer Gas Cylinders has launched its first Non-Limited Life (NLL) medical cylinders, as Covid-19 increases demand for solutions to help millions with respiratory conditions.

The new cylinder will help patients affected by conditions that make breathing difficult, including coronavirus (Covid-19) but also Chronic Obstructive Pulmonary Disease (COPD).

As the world’s largest manufacturer of high-pressure composite and aluminium cylinders, already has more than 15 million of its medical cylinders in use worldwide.

This new Luxfer 1.0 litre NLL carbon composite medical cylinder is its first product offering with a lifespan beyond the typical 15-year and 20-year oxygen cylinder offerings available today.

Luxfer non limited life L6X medical cylinders

Source: Luxfer Gas Cylinders

The product is destined for medical institutions and will go into the hands of healthcare professionals who can help patients who need oxygen therapy on the move.

“This latest innovation, based on decades of cylinder technology development and market leadership, is primed to be at the heart of emergency response situations, medical procedures and life-saving activities for today and in the years to come,” said Mark Lawday, a Director at Luxfer Gas Cylinders.

“With a global aging population, and increasing prevalence of respiratory diseases that affect breathing, this kind of technology is crucial.”

As a direct result of supply related to Covid-19 in early 2020, Luxfer said it experienced an 8% spike in its annual medical orders, from its existing product range.

“As people begin to recover from Covid-19 at home, particularly those who have underlying health conditions that affect their breathing, they may need home oxygen therapy and that will be something we could see as the pandemic plays out,” Lawday said.

“While we can’t say for certain how big an impact this virus will have on home-use portable oxygen delivery systems, it’s clear that technology has a role to play, and products that deliver safe, high performance, durable, cost effective, patient-centric solutions, will be highly prized.”